Skip to content
A clean room at Moderna’s plant in Massachusetts.

A clean room at Moderna’s plant in Massachusetts.

Photographer: Philip Keith for Bloomberg Businessweek
Businessweek
The Big Take

Moderna’s Next Act Is Using mRNA vs. Flu, Zika, HIV, and Cancer

The biotech has reached a $100 billion market cap. But after Covid, the challenges get even bigger.

Updated on

A year ago, Moderna Inc. was an unprofitable company with no marketed products and a promising but totally unproven technology. None of its experimental drugs and vaccines had ever completed a large-scale trial. Experts were divided on how well the mRNA-based Covid-19 vaccine it was about to enter in a Phase III trial would stack up against older, more established vaccine technologies.

Megaphone.fm: Moderna's Next Move by Bloomberg Audio